This study evaluated clinical efficacy and safety of dinutuximab beta as first-line maintenance therapy in a real-world setting.<h4>Methods</h4>We retrospectively analyzed pediatric patients newly diagnosed with high-risk NB who after induction and consolidation therapy, received dinutuximab beta combined with granulocyte-macrophage colony-stimulating factor and isotretinoin, with or without chemotherapy. The gene discussed is CSF2; the disease is neuroblastoma.